You are here: Industry Insights > Cosmo

News List

RedHill and Cosmo Strengthen Manufacturing Agreements contractpharma
February 20, 2021
Secures manufacturing capacity of Movantik for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.
RedHill and Cosmo Expand Opaganib Manufacturing Deal contractpharma
February 03, 2021
New agreement expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study.
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals prnasia
January 29, 2021
RedHill Biopharma Ltd. announced a manufacturing agreement with Cosmo Pharmaceuticals NV to further expand manufacturing capacity for opaganib (Yeliva®, ABC294640), to address prospective demand subsequent to potential global emergency use authorizations.
Cosmo Pharmaceuticals Announces Submission of Remimazolam NDA to FDA drugs
April 17, 2019
Cosmo Pharmaceuticals NV informed that the Remimazolam NDA has been submitted to FDA.
Cosmo’s diarrhoea drug approved, threatening Salix’ cash cow pharmaphorum
November 27, 2018
Ireland’s Cosmo Pharma claimed FDA approval for its traveller’s diarrhoea drug Aemcolo, which some analysts say could be a big threat to a rival drug sold by Bausch Health’s Salix unit.
Cosmo wins FDA green light to challenge Bausch's Xifaxan fiercepharma
November 22, 2018
Bausch Health has yet to fully recover from its tainted past, and a new threat in the form of a rival to its top-seller Xifaxan could pile more pressure on the drugmaker.